Published on PM360, April 2, 2018 The shift to value-based care and outcomes contracting type programs present the opportunity to align stakeholder interests around value and demonstrate a commitment to improving clinical and cost outcomes. From earlier detection to more precision management, the opportunities for pharma to partner around outcomes and value are growing. Win-wins[…]
March 28, 2018 – 2 PM ET What if you could use predictive models like biomarkers to pre-emptively screen and more effectively target patients who are more likely to respond to your drug in trials and in practice? What if you could rapidly answer questions on comparative treatment outcomes and predict those most likely to[…]
Published on HealthEconomics.com on January 3, 2018 As artificial intelligence (AI) and Big Data are lauded for their potential uses in life sciences and healthcare, it is becoming difficult to differentiate between the myriad of terms and technologies and their real value in advancing real-world evidence (RWE). In this article, we explore key AI[…]
January 30, 2018 – 11 am – 12 pm ET – Register Fibrotic diseases, such as non-alcoholic steatohepatitis (NASH), are responsible for 45% of US deaths a year. With a growing occurrence and few treatment options, more research is needed to better understand natural history and progression of these diseases, treatments and outcomes. This session[…]
November 28, 2017 – Dr. Richard Gliklich As artificial intelligence and advanced analytics are increasingly lauded for uses in life sciences and healthcare, it’s becoming difficult to differentiate between the different terms, to understand what is real and what is hype, and to understand how to best leverage these technologies for advancing real-world evidence and[…]
